ClinicalTrials.gg
RecruitingNCT07700953Updated Jul 27, 2026

A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants

A Phase 1 interventional study of ABSK-011 Capsules and omeprazole enteric-coated tablets in Healthy Participants, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study consists of two parts: Part A and Part B. Part A is a single-center, randomized, open-label, three-period study intended to evaluate the effects of low-fat and high-fat meals on the pharmacokinetic profiles of ABSK-011 Capsules. A total of 15 healthy participants are planned to be enrolled. Participants will be randomized to Sequence A, Sequence B or Sequence C at a 1:1:1 ratio and receive a single oral dose of ABSK-011 (50 mg × 4) on three separate occasions with a 4-day washout interval between administrations. 39 PK blood sampling time points will be collected in Part A.

Part B is a single-center, open-label, fixed-sequence study designed to assess the impact of multiple oral doses of omeprazole enteric-coated tablets on the pharmacokinetic profiles of ABSK-011 Capsules. 15 healthy participants are planned for enrollment. On Day 1 of Cycle 1 (C1D1), participants will receive 200 mg ABSK-011 Capsules in the morning after a low-fat meal. From Day 1 to Day 5 of Cycle 2 (C2D1-C2D5), participants will take 40 mg omeprazole enteric-coated tablets orally once daily under fasted conditions. 26 PK blood sampling time points will be collected in Part B.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects aged 18 to 45 years (inclusive) at screening;
  2. Weight ≥ 50.0 kg (male) or ≥ 45.0 kg (female);
  3. Normal or abnormal but not results in medical history, physical examination, clinical laboratory tests and other relevant examinations as assessed by the investigator at Screening;
  4. Male or female subjects of must agree to use effective methods of during the study and within 6 months after the last dose of product;
  5. Willing to participate in this study, understand the study procedures and sign the form prior to screening; willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with medical history or existing diseases of motor system, neuropsychiatric system, endocrine system, blood circulatory system, respiratory system, digestive system, urinary system, reproductive system, and other abnormalities, and those determined by the investigator to be ;
  2. Known allergic history to food, environment, experimental drug ABSK-011 or other drugs;
  3. Participants who have participated in other clinical trials and used other clinical trial drugs or test devices within 3 months before or during the screening period, or plan to participate in other clinical trials during the study period, or participants who do not participate in clinical trials themselves;
  4. have previously participated in this study or any other study related to ABSK-011 as a subject and have taken ABSK-011;
  5. Patients who had used proton pump inhibitors (including omeprazole, Lansoprazole, Rabeprazole, pantoprazole, etc.) within 14 days before the first dose;
  6. Those who have used strong inhibitors or inducers of (including grapefruit juice, grapefruit hybrids, pomegranates, star fruits, grapefruits, Seville oranges and fruit juices or other processed products) within 14 days before the first dose, or have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products;
  7. For those who have used CYP2C19 inhibitors or inducers (including fluoxetine, fluvoxamine, ticlopidine, rifamepine) within 14 days before the first dose, (Part B only);
  8. There are factors that significantly affect drug absorption, distribution, metabolism and excretion, such as inability to take oral experimental drugs (dysphagia), significant nausea, vomiting and malabsorption, history of gastric or intestinal surgery, or other surgical history that affects drug absorption, distribution, metabolism and excretion (except appendicitis surgery);
  9. Patients with needle fainting, blood fainting history, or inability to tolerate venipunction, or difficulty in blood collection;
  10. Blood donation or heavy blood loss (≥400ml) within 3 months before or during screening (except female menstrual period);
  11. Have special dietary requirements, can not comply with the unified diet (such as the standard meal food intolerance, lactose intolerance, etc.) and the corresponding regulations, or have swallowing difficulties;
  12. Those who do not wish to comply with the dietary requirements/restrictions during the study period, which are: (i) Only consume meals provided by the study center during hospitalization; (ii) Avoid P-gp inhibitors throughout the study period;(iii) Avoid moderate and strong CYP3A4 inhibitors or inducers throughout the study period;(iv) Avoid other strong CYP2C19 inhibitors or inducers throughout the study period.
  13. Those who consumed more than 14 units of alcohol per week in the 3 months prior to screening (1 unit of alcohol is about 360mL beer or 45mL spirits with 40% alcohol or 150mL wine), or whose alcohol breath test results were > 0mg/100ml, or those who cannot abstain from alcohol during the study;
  14. Smokers who smoked more than 5 cigarettes per day (or a corresponding amount of tobacco or nicotine products) in the 3 months prior to screening; Or unable to stop using any tobacco products during the trial;
  15. People who had excessive methylxanthine/caffeine consumption in the past 6 months (excess consumption was defined as consuming more than 6 units of caffeine per day, with 1 unit of caffeine equivalent to 177 ml of coffee, 355 ml of tea, 355 ml of cola, or 85 grams of chocolate), Or were unwilling to comply with the methylxanthine/caffeine use restrictions in 5.3.3 during the study period, or had a known history of substance abuse or screened positive for substance abuse;
  16. surface antigen, treponema pallidum antibody, antibody to , antibody to antibody were abnormal and were clinically significant determined by the investigator;
  17. Participants with a history of bacterial, fungal, parasitic, viral (excluding nasopharyngitis) or mycobacterium infection within 45 days prior to the first administration, or imaging findings (chest radiograph) supporting related infections (as determined by the investigator);
  18. had been vaccinated within 2 months prior to the first dose, or intended to be vaccinated throughout the study period;
  19. Any other factors that the investigator considers inappropriate for participation in this trial, which may affect the participant's adherence to the protocol, interfere with the interpretation of the study results, or expose the participant to risk. Or subjects withdraw from the experiment for their own reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Participants in Sequence A will receive 200 mg ABSK-011 Capsules orally under fasted conditions on the morning of Day 1 of Cycle 1 (C1D1), followed by 200 mg ABSK-011 Capsules after a low-fat meal on the morning of Day 1 of Cycle 2 (C2D1), and 200 mg ABSK-011 Capsules after a high-fat meal on the morning of Day 1 of Cycle 3 (C3D1).

    Drug: ABSK-011 Capsules

  • Experimental
    Sequence B

    Participants in Sequence B will receive 200 mg ABSK-011 Capsules after a low-fat meal on the morning of C1D1, 200 mg ABSK-011 Capsules after a high-fat meal on the morning of C2D1, and 200 mg ABSK-011 Capsules under fasted conditions on the morning of C3D1.

    Drug: ABSK-011 Capsules

  • Experimental
    Sequence C

    Participants in Sequence C will receive 200 mg ABSK-011 Capsules after a high-fat meal on the morning of C1D1, 200 mg ABSK-011 Capsules under fasted conditions on the morning of C2D1, and 200 mg ABSK-011 Capsules after a low-fat meal on the morning of C3D1.

    Drug: ABSK-011 Capsules

  • Experimental
    Omeprazole + Low-Fat Meal + ABSK-011

    Participants will receive 200 mg ABSK-011 Capsules following a low-fat meal on the morning of Day 1 of Cycle 1 (C1D1). During Days 1 to 5 of Cycle 2 (C2D1-C2D5), participants will take 40 mg omeprazole enteric-coated tablets orally once daily under fasted conditions. On C2D5, a low-fat meal will be provided 1.5 hours (±1 minute) after omeprazole administration, and a single oral dose of 200 mg ABSK-011 Capsules will be administered 2 hours (±1 minute) after omeprazole intake.

    Drug: ABSK-011 Capsules · Drug: omeprazole enteric-coated tablets

Interventions

  • ABSK-011 Capsules

  • Drugomeprazole enteric-coated tablets

    ABSK-011 Capsules、omeprazole enteric-coated tablets

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Peak concentration, the maximum observed plasma concentration of ABSK-011

    Time frame: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours,5 hours, 6 hours, 10 hours, 24 hours, 48 hours,72 hours

  2. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

    Area under the plasma concentration-time curve from time 0 to infinity of ABSK-011

    Time frame: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours,5 hours, 6 hours, 10 hours, 24 hours, 48 hours,72 hours

  3. Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUClast)

    Area under the plasma concentration-time curve from time 0 to the last measurable concentration of ABSK-011

    Time frame: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours,5 hours, 6 hours, 10 hours, 24 hours, 48 hours,72 hours

  4. Time to maximum plasma concentration (tmax)

    Time to maximum plasma concentration of ABSK-011

    Time frame: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours,5 hours, 6 hours, 10 hours, 24 hours, 48 hours,72 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Aug 2026, 0 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Aug 10, 2026
CompletionEst.
Aug 10, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07700953
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jul 21, 2026
Primary completion
Aug 10, 2026 (estimated)
Completion
Aug 10, 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

Shuqi Zeng, Doctor
Contact
clinical@abbisko.cn
+86-021-68910052
Yiqing Zhao, Bachelor
principal investigator · Affiliated Hospital of Jiangnan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irpagratinib

Start the discussion